Breaking the Bad News to the Bereaved Family and Their Reactions
NCT ID: NCT04385628
Last Updated: 2020-05-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2019-04-25
2020-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Family Involvement in ICU
NCT06770751
Predictors of Mortality in Traumatic Brain Injury Patients in Intensive Care Unit
NCT06183749
Effect of FAST HUGS WITH ICU Approach on Length of Intensive Care Unit Stay in Patients With Hypoxic Respiratory Failure
NCT06901050
Burnout and Approach to Bereavement Initiatives in a Medical Intensive Care Unit (ICU)
NCT03398460
Views of Nurses on Alarm Fatigue in ICUs
NCT05163340
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Grief reaction is unique, and it will differ from one individual to another. Possible reactions of relatives of patients during the death notification (Emotional Reactions)
1. Regular response; In this case, the relatives of the patients often describe the event as expected or my patient is now free from suffering.
2. Initial shock reaction; It may be complete desperation and a state of closure,
3. Denial- This is an initial defense mechanism after the unexpected, devastating news, and it should be recognized and tolerated. Acceptance may be possible by encouraging the relatives to view the body of the deceased, especially to those relatives who were not present at the time of death
4. Anger- This is a common reaction after the sudden death of a beloved relative. The expression of this anger can vary from mild irritation to violent behavior. This can be expressed on self, hospital staff, or any other person. Anger will gradually diminish once expressed
5. Guilt- This is nothing but the inward expression of anger and self-blame. Consoling words of the health care team will help to do away with this emotion.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
FAMILY_BASED
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Relatives of patients hospitalized in the intensive care unit
Demographic data of the relative of the patient (age, proximity, educational background, patient co-existence, ethnicity, marital status, number of children, history of psychological treatment and the presence of an intensive care treatment history of any family member before) will be recorded. After the 3rd, 10th, and 30th days of patient admission, and once a month, the patient satisfaction survey will be filled face to face during informing the patient's relative. These three main data (Demographic data of the patient relatives, the most recent satisfaction questionnaire and emotional reactions observed while reporting death) will be evaluated and interpreted.
the patient' relatives satisfaction questionnaire
The patient' relatives satisfaction questionnaire will be filled face to face during informing the patient's relatives after the 3rd, 10th, and 30th days of patient admission, and once a month. We will evaluate the most recent questionnaire.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
the patient' relatives satisfaction questionnaire
The patient' relatives satisfaction questionnaire will be filled face to face during informing the patient's relatives after the 3rd, 10th, and 30th days of patient admission, and once a month. We will evaluate the most recent questionnaire.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalization period\> 72 hours in intensive care unit -
Exclusion Criteria
* Those who have a stay in ICU \<72 hours
* Currently receiving psychological medication
* Those who do not accept one of the legal heirs to participate in the study
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bülent Barış Güven
medical doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
selçuk Taşçı
Role: STUDY_CHAIR
Sultan Abdulhamidhan Training Hospital
ayşın ersoy
Role: STUDY_DIRECTOR
Sultan Abdulhamidhan Training Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sultan 2.Abdulhamidhan training hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Naik SB. Death in the hospital: Breaking the bad news to the bereaved family. Indian J Crit Care Med. 2013 May;17(3):178-81. doi: 10.4103/0972-5229.117067.
Jurkovich GJ, Pierce B, Pananen L, Rivara FP. Giving bad news: the family perspective. J Trauma. 2000 May;48(5):865-70; discussion 870-3. doi: 10.1097/00005373-200005000-00009.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
48670771-514.10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.